Zhang Luo, Song Xing, Shao Yingjie, Wu Changping, Jiang Jingting
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
Oncotarget. 2018 Jan 4;9(37):24821-24829. doi: 10.18632/oncotarget.23892. eCollection 2018 May 15.
Accumulated studies have shown the important role of Midkine (MDK) protein in various solid tumors and indicated its correlation with patients' survival. This meta-analysis was performed to further explore the prognostic value of MDK expression in solid tumors.
We collected the literatures through searching PubMed, Embase and the Cochrane Library (last up to April 10, 2017) to assess the effect of MDK on survival in solid tumor patients. The STATA 12.0 software was used for the meta-analysis. Fixed-effects models or random-effects models were used to estimate the pooled hazard ratios (HRs) for overall survival (OS).
A total of 2097 patients from 17 observational studies were summarized. High expression of MDK was notably associated with worse OS in solid tumor patients. (pooled HR = 1.96; 95% CI = 1.67-2.31). The subgroup analysis of tumor type demonstrated negative impact of elevated MDK on OS in most solid tumor patients ( < 0.05), while MDK had no relevance with OS in the patients with OSCC (pooled HR = 1.68; 95% CI = 0.84-3.36; 0.145) or HNSCC (pooled HR = 1.56; 95% CI = 0.96-2.51; 0.075).
The present meta-analysis clarifies that MDK is a potential prognostic biomarker in solid tumor patients. Future large-scale prospective clinical trials are needed to determine the prognostic value of MDK in solid tumor patients.
大量研究表明中期因子（MDK）蛋白在多种实体瘤中发挥重要作用，并提示其与患者生存相关。本荟萃分析旨在进一步探讨MDK表达在实体瘤中的预后价值。
通过检索PubMed、Embase和Cochrane图书馆（截至2017年4月10日）收集文献，以评估MDK对实体瘤患者生存的影响。采用STATA 12.0软件进行荟萃分析。采用固定效应模型或随机效应模型估计总生存（OS）的合并风险比（HRs）。
共纳入17项观察性研究的2097例患者。实体瘤患者中MDK高表达显著与较差的OS相关（合并HR = 1.96；95%CI = 1.67 - 2.31）。肿瘤类型的亚组分析显示，大多数实体瘤患者中MDK升高对OS有负面影响（<0.05），而在口腔鳞状细胞癌（OSCC）患者（合并HR = 1.68；95%CI = 0.84 - 3.36；P = 0.145）或头颈部鳞状细胞癌（HNSCC）患者（合并HR = 1.56；95%CI = 0.96 - 2.51；P = 0.075）中MDK与OS无关。
本荟萃分析表明，MDK是实体瘤患者潜在的预后生物标志物。未来需要大规模前瞻性临床试验来确定MDK在实体瘤患者中的预后价值。
